These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 30706562

  • 1. Quality and potency profile of eight recombinant isoallergens, largely mimicking total Bet v 1-specific IgE binding of birch pollen.
    Seutter von Loetzen C, Reuter A, Spiric J, Schulenborg T, Bellinghausen I, Völker E, Vogel L, Rösch P, Schiller D.
    Clin Exp Allergy; 2019 May; 49(5):712-723. PubMed ID: 30706562
    [Abstract] [Full Text] [Related]

  • 2. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
    Kahlert H, Suck R, Weber B, Nandy A, Wald M, Keller W, Cromwell O, Fiebig H.
    Int Arch Allergy Immunol; 2008 May; 145(3):193-206. PubMed ID: 17912007
    [Abstract] [Full Text] [Related]

  • 3. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination.
    Vrtala S, Fohr M, Campana R, Baumgartner C, Valent P, Valenta R.
    Vaccine; 2011 Mar 03; 29(11):2140-8. PubMed ID: 21215346
    [Abstract] [Full Text] [Related]

  • 4. Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations.
    Niederberger V, Pauli G, Grönlund H, Fröschl R, Rumpold H, Kraft D, Valenta R, Spitzauer S.
    J Allergy Clin Immunol; 1998 Oct 03; 102(4 Pt 1):579-91. PubMed ID: 9802365
    [Abstract] [Full Text] [Related]

  • 5. Epicutaneous immunotherapy with a hypoallergenic Bet v 1 suppresses allergic asthma in a murine model.
    Siebeneicher S, Reuter S, Wangorsch A, Krause M, Foetisch K, Heinz A, Naito S, Reuter A, Taube C, Vieths S, Scheurer S, Toda M.
    Allergy; 2015 Dec 03; 70(12):1559-68. PubMed ID: 26304061
    [Abstract] [Full Text] [Related]

  • 6. Fagales pollen sensitization in a birch-free area: a respiratory cohort survey using Fagales pollen extracts and birch recombinant allergens (rBet v 1, rBet v 2, rBet v 4).
    Mari A, Wallner M, Ferreira F.
    Clin Exp Allergy; 2003 Oct 03; 33(10):1419-28. PubMed ID: 14519150
    [Abstract] [Full Text] [Related]

  • 7. In vivo Induction of Functional Inhibitory IgG Antibodies by a Hypoallergenic Bet v 1 Variant.
    Aglas L, Bethanis A, Chrusciel P, Stolz F, Gruen M, Jaakkola UM, Jongejan L, Yatkin E, Van Ree R.
    Front Immunol; 2020 Oct 03; 11():2118. PubMed ID: 33013894
    [Abstract] [Full Text] [Related]

  • 8. IgE and allergen-specific immunotherapy-induced IgG4 recognize similar epitopes of Bet v 1, the major allergen of birch pollen.
    Groh N, von Loetzen CS, Subbarayal B, Möbs C, Vogel L, Hoffmann A, Fötisch K, Koutsouridou A, Randow S, Völker E, Seutter von Loetzen A, Rösch P, Vieths S, Pfützner W, Bohle B, Schiller D.
    Clin Exp Allergy; 2017 May 03; 47(5):693-703. PubMed ID: 27770477
    [Abstract] [Full Text] [Related]

  • 9. [Relationship between IgE antibodies to recombinant allergens rBet v 1 and rBet v 2 and food causing oral allergy syndrome in cases of birch-pollen allergy].
    Yamamoto T, Asakura K, Shirasaki H, Himi T.
    Nihon Jibiinkoka Gakkai Kaiho; 2010 Aug 03; 113(8):661-9. PubMed ID: 20845708
    [Abstract] [Full Text] [Related]

  • 10. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season.
    van Hage-Hamsten M, Kronqvist M, Zetterström O, Johansson E, Niederberger V, Vrtala S, Grönlund H, Grönneberg R, Valenta R.
    J Allergy Clin Immunol; 1999 Nov 03; 104(5):969-77. PubMed ID: 10550741
    [Abstract] [Full Text] [Related]

  • 11. Induction of IgE antibodies in mice and rhesus monkeys with recombinant birch pollen allergens: different allergenicity of Bet v 1 and Bet v 2.
    Vrtala S, Mayer P, Ferreira F, Susani M, Sehon AH, Kraft D, Valenta R.
    J Allergy Clin Immunol; 1996 Nov 03; 98(5 Pt 1):913-21. PubMed ID: 8939154
    [Abstract] [Full Text] [Related]

  • 12. Folded or Not? Tracking Bet v 1 Conformation in Recombinant Allergen Preparations.
    Husslik F, Hanschmann KM, Krämer A, Seutter von Loetzen C, Schweimer K, Bellinghausen I, Treudler R, Simon JC, Vogel L, Völker E, Randow S, Reuter A, Rösch P, Vieths S, Holzhauser T, Schiller D.
    PLoS One; 2015 Nov 03; 10(7):e0132956. PubMed ID: 26186356
    [Abstract] [Full Text] [Related]

  • 13. Severe oral allergy syndrome and anaphylactic reactions caused by a Bet v 1- related PR-10 protein in soybean, SAM22.
    Kleine-Tebbe J, Vogel L, Crowell DN, Haustein UF, Vieths S.
    J Allergy Clin Immunol; 2002 Nov 03; 110(5):797-804. PubMed ID: 12417891
    [Abstract] [Full Text] [Related]

  • 14. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System.
    Movérare R, Elfman L, Vesterinen E, Metso T, Haahtela T.
    Allergy; 2002 May 03; 57(5):423-30. PubMed ID: 11972482
    [Abstract] [Full Text] [Related]

  • 15. Different IgE reactivity profiles in birch pollen-sensitive patients from six European populations revealed by recombinant allergens: an imprint of local sensitization.
    Movérare R, Westritschnig K, Svensson M, Hayek B, Bende M, Pauli G, Sorva R, Haahtela T, Valenta R, Elfman L.
    Int Arch Allergy Immunol; 2002 Aug 03; 128(4):325-35. PubMed ID: 12218371
    [Abstract] [Full Text] [Related]

  • 16. Altered IgE epitope presentation: A model for hypoallergenic activity revealed for Bet v 1 trimer.
    Campana R, Vrtala S, Maderegger B, Dall'Antonia Y, Zafred D, Blatt K, Herrmann H, Focke-Tejkl M, Swoboda I, Scheiblhofer S, Gieras A, Neubauer A, Keller W, Valent P, Thalhamer J, Spitzauer S, Valenta R.
    Mol Immunol; 2011 Jan 03; 48(4):431-41. PubMed ID: 21093057
    [Abstract] [Full Text] [Related]

  • 17. Molecular cloning and characterization of a birch pollen minor allergen, Bet v 5, belonging to a family of isoflavone reductase-related proteins.
    Karamloo F, Schmitz N, Scheurer S, Foetisch K, Hoffmann A, Haustein D, Vieths S.
    J Allergy Clin Immunol; 1999 Nov 03; 104(5):991-9. PubMed ID: 10550744
    [Abstract] [Full Text] [Related]

  • 18. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies.
    Vrtala S, Akdis CA, Budak F, Akdis M, Blaser K, Kraft D, Valenta R.
    J Immunol; 2000 Dec 01; 165(11):6653-9. PubMed ID: 11086111
    [Abstract] [Full Text] [Related]

  • 19. IgE-blocking antibodies following SLIT with recombinant Mal d 1 accord with improved apple allergy.
    Sánchez Acosta G, Kinaciyan T, Kitzmüller C, Möbs C, Pfützner W, Bohle B.
    J Allergy Clin Immunol; 2020 Oct 01; 146(4):894-900.e2. PubMed ID: 32259540
    [Abstract] [Full Text] [Related]

  • 20. Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.
    Geroldinger-Simic M, Kinaciyan T, Nagl B, Baumgartner-Durchschlag U, Huber H, Ebner C, Lidholm J, Bartel D, Vieths S, Jahn-Schmid B, Bohle B.
    J Allergy Clin Immunol; 2013 Jan 01; 131(1):94-102. PubMed ID: 22921871
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.